October 07, 2003
IntraBiotics Names Mark L. Perry to Its Board of Directors
Mr. Perry is the Executive Vice President, Operations, of Gilead, an independent biopharmaceutical company that discovers, develops and commercializes therapeutics for infectious diseases.
"Mark has played a key role in making Gilead the successful multinational company that it is today," said Ernest Mario, Ph.D., Chairman of IntraBiotics. "He brings a wealth of operating experience and a track record of success at Gilead in markets and disease areas related to those we are beginning to focus on at IntraBiotics. As a result, Mark will add direct and immediate value to IntraBiotics as our executive team seeks to develop our lead product iseganan for the prevention of ventilator-associated pneumonia (VAP)."
"IntraBiotics is going through a very exciting evolution as it seeks to address the major unmet medical need of VAP with iseganan, a novel drug in a new class," said Mr. Perry. "I look forward to working with CEO Hank Fuchs, M.D., and the rest of the IntraBiotics Board and senior management team as they execute the clinical and commercial activities necessary to fully capitalize on this opportunity. I also hope to help IntraBiotics identify other product opportunities that leverage their expertise and capabilities."
Mr. Perry joined Gilead in July 1994 as Vice President, General Counsel, and Secretary and assumed the additional responsibilities of Chief Financial Officer in July 1996. Mr. Perry was promoted to Senior Vice President in January 1998, in February 2000 was promoted to Senior Vice President, Operations and in November 2000 was promoted to Executive Vice President, Operations. From 1981 to 1994, Mr. Perry was with the law firm of Cooley Godward LLP in San Francisco and Palo Alto, California. Mr. Perry was an associate with Cooley Godward from 1981 to 1987, and a partner from 1987 to 1994. Mr. Perry received his J.D. from the University of California, Davis and is a member of the California bar. Mr. Perry also serves on the Board of DNA Sciences, Inc.
Iseganan hydrochloride (HCl) oral solution is a broad-spectrum antimicrobial peptide that functions by a novel mechanism of action, which may substantially reduce the likelihood of microbial resistance. Iseganan is the first in a new class of investigational peptide drugs known as protegrins, which are naturally-occurring substances found in mammals where they form part of the first line of defense against invading bacteria and fungi.
About Ventilator-Associated Pneumonia (VAP)
Pneumonia is the most common infection among ventilated patients in the intensive care unit. The longer a patient is ventilated, the higher the risk of developing VAP. Approximately 15-30% of patients receiving mechanical ventilation for more than 48 hours get VAP. The Company estimates that over 1 million patients annually are mechanically ventilated for more than 48 hours in North America, Western Europe and Japan combined, making VAP a significant unmet medical need. Despite the use of potent, broad-spectrum, antibiotics, patients who develop VAP generally remain dependent on artificial ventilation and remain in the intensive care unit for longer periods of time than patients who do not develop VAP. As a consequence, studies have demonstrated that patients who develop VAP can incur more than $40,000 in additional hospital charges.
IntraBiotics Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on developing iseganan for the prevention of VAP. Additional information is available at the Company's website: www.intrabiotics.com.
Certain statements in this press release contain forward-looking information and are subject to risks and uncertainties, such as statements regarding product development and clinical developments. As such, they are subject to the occurrence of many events outside of IntraBiotics' control and are subject to various risk factors that could cause IntraBiotics' results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the inherent risks of product development failure; uncertainty of the timing, cost, extent and results of clinical trials; risk of delays in conducting clinical trials due to factors such as slower than expected rate of patient recruitment, additional regulatory requests, inability to manufacture sufficient quantities of materials used for clinical trials, difficulties with clinical supplies or unforeseen safety issues; regulatory risks, risks related to proprietary rights, market acceptance and competition; and the Company's ability to raise capital through private or public financings when needed or on favorable terms. These risk factors are more fully described in documents on file with the Securities and Exchange Commission including, but not limited to, our Form 10-Q for the Quarterly Period ended June 30, 2003 and our Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2002.